Cargando…
Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19
Autores principales: | DiNicolantonio, James J, Barroso-Arranda, Jorge, McCarty, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476419/ https://www.ncbi.nlm.nih.gov/pubmed/32895293 http://dx.doi.org/10.1136/openhrt-2020-001350 |
Ejemplares similares
-
Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors
por: DiNicolantonio, James J, et al.
Publicado: (2021) -
Melatonin may decrease risk for and aid treatment of COVID-19 and other RNA viral infections
por: DiNicolantonio, James J, et al.
Publicado: (2021) -
Autophagy-induced degradation of Notch1, achieved through intermittent fasting, may promote beta cell neogenesis: implications for reversal of type 2 diabetes
por: DiNicolantonio, James J, et al.
Publicado: (2019) -
Azithromycin and glucosamine may amplify the type 1 interferon response to RNA viruses in a complementary fashion
por: DiNicolantonio, James J., et al.
Publicado: (2020) -
Decreased magnesium status may mediate the increased cardiovascular risk associated with calcium supplementation
por: DiNicolantonio, James J, et al.
Publicado: (2017)